Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

National Heart, Lung, and Blood Institute (NHLBI): Clinical Trials & FDA Approval Profile

National Heart, Lung, and Blood Institute (NHLBI) (Global / Institutional) sponsors 30 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 15 active protocols (8 recruiting now), 9 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)20.0%
Median Closed Enrollment vs National (145 pts)15 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Heart, Lung, and Blood Institute (NHLBI)
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)30
Active Pipeline (Recruiting Now)15 (8)
Completed vs Stopped Early9 / 6 (20.0%)
Median Closed Actual Enrollment15 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Heart, Lung, and Blood Institute (NHLBI)
Hospital Research SiteLocationShared Protocols
NIH Clinical CenterBethesda, MD30

Explore interactive annual charts and M&A subsidiary rollups in the National Heart, Lung, and Blood Institute (NHLBI) Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI